Regulatory flexibility can make continuous improvement possible.
Tim Schofield
Advertisement
Tim Schofield is the director of US regulatory affairs at GlaxoSmithKline
Articles by Tim Schofield
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Orion and Abzena Collaboration Highlights Integrated Antibody Manufacturing Advances
2
BioPharm Weekly News Roundup—Week of Oct. 20, 2025
3
SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks
4
Ask the Expert: Commenting on Draft Regulations
5
